Cargando…

Pleiotropic Effects of Heparins: From Clinical Applications to Molecular Mechanisms in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is a major health problem worldwide and most cases are incurable because of late presentation. It is the most common primary neoplasm of the liver and often arises in the context of a chronic liver disease that impairs coagulation. Portal vein thrombosis (PVT) is a com...

Descripción completa

Detalles Bibliográficos
Autores principales: Korhan, Peyda, Yılmaz, Yeliz, Bağırsakçı, Ezgi, Güneş, Ayşim, Topel, Hande, Carr, Brian I., Atabey, Neşe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6217885/
https://www.ncbi.nlm.nih.gov/pubmed/30425976
http://dx.doi.org/10.1155/2018/7568742
_version_ 1783368368417406976
author Korhan, Peyda
Yılmaz, Yeliz
Bağırsakçı, Ezgi
Güneş, Ayşim
Topel, Hande
Carr, Brian I.
Atabey, Neşe
author_facet Korhan, Peyda
Yılmaz, Yeliz
Bağırsakçı, Ezgi
Güneş, Ayşim
Topel, Hande
Carr, Brian I.
Atabey, Neşe
author_sort Korhan, Peyda
collection PubMed
description Hepatocellular carcinoma (HCC) is a major health problem worldwide and most cases are incurable because of late presentation. It is the most common primary neoplasm of the liver and often arises in the context of a chronic liver disease that impairs coagulation. Portal vein thrombosis (PVT) is a common complication of HCC that is associated with a poor prognosis. Heparin derivatives are widely used in the management of venous thromboembolism (VTE). Among them low molecular weight heparin (LMWH) favorably influences the survival in patients with advanced cancer, including HCC. Due to their pleiotropic function, heparins affect tumorigenesis in many ways and may promote or hamper tumorigenic transformation depending on the cancer type and cancer stage along with their structural properties and concentration. Thus, their application as an antithrombotic along with the conventional therapy regime should be carefully planned to develop the best management strategies. In this review, we first will briefly review clinical applications of heparin derivatives in the management of cancer with a particular focus on HCC. We then summarize the state of knowledge whereby heparin can crosstalk with molecules playing a role in hepatocarcinogenesis. Lastly, we highlight new experimental and clinical research conducted with the aim of moving towards personalized therapy in cancer patients at risk of thromboembolism.
format Online
Article
Text
id pubmed-6217885
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-62178852018-11-13 Pleiotropic Effects of Heparins: From Clinical Applications to Molecular Mechanisms in Hepatocellular Carcinoma Korhan, Peyda Yılmaz, Yeliz Bağırsakçı, Ezgi Güneş, Ayşim Topel, Hande Carr, Brian I. Atabey, Neşe Can J Gastroenterol Hepatol Review Article Hepatocellular carcinoma (HCC) is a major health problem worldwide and most cases are incurable because of late presentation. It is the most common primary neoplasm of the liver and often arises in the context of a chronic liver disease that impairs coagulation. Portal vein thrombosis (PVT) is a common complication of HCC that is associated with a poor prognosis. Heparin derivatives are widely used in the management of venous thromboembolism (VTE). Among them low molecular weight heparin (LMWH) favorably influences the survival in patients with advanced cancer, including HCC. Due to their pleiotropic function, heparins affect tumorigenesis in many ways and may promote or hamper tumorigenic transformation depending on the cancer type and cancer stage along with their structural properties and concentration. Thus, their application as an antithrombotic along with the conventional therapy regime should be carefully planned to develop the best management strategies. In this review, we first will briefly review clinical applications of heparin derivatives in the management of cancer with a particular focus on HCC. We then summarize the state of knowledge whereby heparin can crosstalk with molecules playing a role in hepatocarcinogenesis. Lastly, we highlight new experimental and clinical research conducted with the aim of moving towards personalized therapy in cancer patients at risk of thromboembolism. Hindawi 2018-10-22 /pmc/articles/PMC6217885/ /pubmed/30425976 http://dx.doi.org/10.1155/2018/7568742 Text en Copyright © 2018 Peyda Korhan et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Korhan, Peyda
Yılmaz, Yeliz
Bağırsakçı, Ezgi
Güneş, Ayşim
Topel, Hande
Carr, Brian I.
Atabey, Neşe
Pleiotropic Effects of Heparins: From Clinical Applications to Molecular Mechanisms in Hepatocellular Carcinoma
title Pleiotropic Effects of Heparins: From Clinical Applications to Molecular Mechanisms in Hepatocellular Carcinoma
title_full Pleiotropic Effects of Heparins: From Clinical Applications to Molecular Mechanisms in Hepatocellular Carcinoma
title_fullStr Pleiotropic Effects of Heparins: From Clinical Applications to Molecular Mechanisms in Hepatocellular Carcinoma
title_full_unstemmed Pleiotropic Effects of Heparins: From Clinical Applications to Molecular Mechanisms in Hepatocellular Carcinoma
title_short Pleiotropic Effects of Heparins: From Clinical Applications to Molecular Mechanisms in Hepatocellular Carcinoma
title_sort pleiotropic effects of heparins: from clinical applications to molecular mechanisms in hepatocellular carcinoma
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6217885/
https://www.ncbi.nlm.nih.gov/pubmed/30425976
http://dx.doi.org/10.1155/2018/7568742
work_keys_str_mv AT korhanpeyda pleiotropiceffectsofheparinsfromclinicalapplicationstomolecularmechanismsinhepatocellularcarcinoma
AT yılmazyeliz pleiotropiceffectsofheparinsfromclinicalapplicationstomolecularmechanismsinhepatocellularcarcinoma
AT bagırsakcıezgi pleiotropiceffectsofheparinsfromclinicalapplicationstomolecularmechanismsinhepatocellularcarcinoma
AT gunesaysim pleiotropiceffectsofheparinsfromclinicalapplicationstomolecularmechanismsinhepatocellularcarcinoma
AT topelhande pleiotropiceffectsofheparinsfromclinicalapplicationstomolecularmechanismsinhepatocellularcarcinoma
AT carrbriani pleiotropiceffectsofheparinsfromclinicalapplicationstomolecularmechanismsinhepatocellularcarcinoma
AT atabeynese pleiotropiceffectsofheparinsfromclinicalapplicationstomolecularmechanismsinhepatocellularcarcinoma